| Buffalo Clinic, Monticello Clinic, Albertville/st.michael Clinic, | |
|
1700 Highway 25 N Buffalo MN 55313-1930 | |
| (763) 682-1313 | |
| (763) 684-3790 |
| Full Name | Buffalo Clinic, Monticello Clinic, Albertville/st.michael Clinic, |
|---|---|
| Speciality | Clinic/Center |
| Location | 1700 Highway 25 N, Buffalo, Minnesota |
| Authorized Official Name and Position | Jason S Halvorson (PRESIDENT) |
| Authorized Official Contact | 7632952921 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Buffalo Clinic, Monticello Clinic, Albertville/st.michael Clinic, 1700 Highway 25 N Buffalo MN 55313-1930 Ph: (763) 682-1313 | Buffalo Clinic, Monticello Clinic, Albertville/st.michael Clinic, 1700 Highway 25 N Buffalo MN 55313-1930 Ph: (763) 682-1313 |
| NPI Number | 1184664674 |
|---|---|
| Provider Enumeration Date | 06/07/2006 |
| Last Update Date | 08/12/2016 |
| Medicare PECOS PAC ID | 1153233796 |
|---|---|
| Medicare Enrollment ID | O20031103000458 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184664674 | NPI | - | NPPES |
| 222310400 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM1300X | Clinic/center - Multi-specialty | 520 (Minnesota) | Primary |
| Provider Name | Arati K Gudage |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1154347953 PECOS PAC ID: 6608778725 Enrollment ID: I20040121000202 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Dale E Lawrence |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1760403562 PECOS PAC ID: 6305737297 Enrollment ID: I20040322000667 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Jason S Halvorson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1033139159 PECOS PAC ID: 2860304300 Enrollment ID: I20040430000145 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Ositadimma C Ugwu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1013989417 PECOS PAC ID: 0042281628 Enrollment ID: I20040805000792 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Michael D Oborsky |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1053477406 PECOS PAC ID: 3173504867 Enrollment ID: I20041115000059 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Joy L Westerdahl |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1922089937 PECOS PAC ID: 1951293802 Enrollment ID: I20050523000184 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Corey L Martin |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1447272760 PECOS PAC ID: 8729071196 Enrollment ID: I20050610000126 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Teresa E Wrobbel |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1912916933 PECOS PAC ID: 8224940762 Enrollment ID: I20050711000161 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Joseph Kyle Mahoney |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1245244003 PECOS PAC ID: 5193758977 Enrollment ID: I20050913000421 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Deborah L Mahoney |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1376565176 PECOS PAC ID: 3375500291 Enrollment ID: I20051229000136 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Marisa D Moline |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962425082 PECOS PAC ID: 0749296705 Enrollment ID: I20060228000520 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Kari J Fabian |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1700816378 PECOS PAC ID: 7810063864 Enrollment ID: I20080827000727 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Franklin O Anderson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1235303793 PECOS PAC ID: 0446314991 Enrollment ID: I20090127000617 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Mark D Nelson |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1487656344 PECOS PAC ID: 1052476439 Enrollment ID: I20090616000334 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Natalie R Roeser |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1497928337 PECOS PAC ID: 4385780154 Enrollment ID: I20091008000060 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Jolyn S Halvorson |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1659391779 PECOS PAC ID: 3476680935 Enrollment ID: I20100415000255 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Glenn G Nemec |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1578578068 PECOS PAC ID: 1153233606 Enrollment ID: I20100511000077 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Kristina A Loken |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1609898444 PECOS PAC ID: 3173613643 Enrollment ID: I20100511000206 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Janice C Pletsch |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1336155928 PECOS PAC ID: 0941112494 Enrollment ID: I20100511000313 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Rajan Jhanjee |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1871513929 PECOS PAC ID: 8729178298 Enrollment ID: I20100511000658 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Glen A Deutsch |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1134148851 PECOS PAC ID: 2365354909 Enrollment ID: I20100511000690 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Bernice M Kolb |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1740200625 PECOS PAC ID: 5991617433 Enrollment ID: I20100511000762 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Cynthia L Larson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1013938802 PECOS PAC ID: 1355253899 Enrollment ID: I20100922000910 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | William J Affeldt |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1013950203 PECOS PAC ID: 4587856968 Enrollment ID: I20101004000692 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Megan Tiffany Otis |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1437392586 PECOS PAC ID: 3779752464 Enrollment ID: I20110815000564 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Matthew F Hoffman |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1780848440 PECOS PAC ID: 5395916415 Enrollment ID: I20110922000037 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Sarah R Janzen |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1831472661 PECOS PAC ID: 2365617511 Enrollment ID: I20111216000135 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Abby Rae Labounty |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1528359452 PECOS PAC ID: 9032365101 Enrollment ID: I20120806000020 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Anne M Pribyl |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447506126 PECOS PAC ID: 8527218643 Enrollment ID: I20121026000351 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | James Christopher Lorge |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1376749192 PECOS PAC ID: 7719134865 Enrollment ID: I20130827000196 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Donnetta L Wallace |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1922436914 PECOS PAC ID: 5799912895 Enrollment ID: I20131217001429 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Teresa J Devine |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1255771911 PECOS PAC ID: 3375769110 Enrollment ID: I20140730002710 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Lynn N Lampi |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801202932 PECOS PAC ID: 5991027088 Enrollment ID: I20141126001256 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Mallory L Gustin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437542016 PECOS PAC ID: 1456670066 Enrollment ID: I20150504001004 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Carla M Schultz |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1003100595 PECOS PAC ID: 7517257157 Enrollment ID: I20160609001507 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Christopher D Elness |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1649622200 PECOS PAC ID: 8426337205 Enrollment ID: I20161118000658 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Jessica A Borgstrom |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1467994962 PECOS PAC ID: 0840572236 Enrollment ID: I20170119001657 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Danielle M Schirm |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1447513072 PECOS PAC ID: 7911141858 Enrollment ID: I20170726001928 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Heidi Renae Nichol |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1538514658 PECOS PAC ID: 9931489895 Enrollment ID: I20170812000338 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Beth D Brinkman |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1558717587 PECOS PAC ID: 1850683699 Enrollment ID: I20180103001681 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Lindsey C Latteman Fensch |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1891108627 PECOS PAC ID: 2163771262 Enrollment ID: I20180823000347 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Amanda R Zehrer |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1699174508 PECOS PAC ID: 4981954633 Enrollment ID: I20180830002023 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Emily M Lawrence |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1124515986 PECOS PAC ID: 2567710270 Enrollment ID: I20190808001353 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Kari J Standfuss |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750941324 PECOS PAC ID: 1658609946 Enrollment ID: I20190823003005 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Jacquelyn Darlene Harman |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1992233993 PECOS PAC ID: 8022388966 Enrollment ID: I20200915000040 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Cory R Simning |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1689171894 PECOS PAC ID: 9032466453 Enrollment ID: I20210825003818 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
| Provider Name | Cassandra Marie Hirman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255116554 PECOS PAC ID: 1951758200 Enrollment ID: I20231108003264 |
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
News Archive
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).
Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has presented the 2010 list of MAK and BAT values containing new data on 61 substances. These values for the classification of health hazards constituted by work area substances have been adjusted this year.
Experts from the University of Exeter, the Met Office, Public Health England, London School of Hygiene & Tropical Medicine, and University of Bristol will be involved in the project which, over three years, will develop an internet-based platform that will link health data with information on the environment and climate.
› Verified 9 days ago
Regenerative Medicine Ctr Mn Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 201 5th St Ne Ste 4, Buffalo, MN 55313 Phone: 763-682-0611 | |
Allina Health Clinic - Buffalo Crossroads Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 755 Crossroads Campus Dr Ne, Buffalo, MN 55313 Phone: 763-684-6300 | |
Intentional Wellness Solutions Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 30 1st Ave Ne Ste 7, Buffalo, MN 55313 Phone: 763-400-8177 Fax: 304-301-3047 | |
Neisen Pain Clinic Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 302 Brighton Ave S, Buffalo, MN 55313 Phone: 763-595-1411 Fax: 763-595-1412 | |
Allina Health Clinic - Buffalo Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 303 Catlin St, Buffalo, MN 55313 Phone: 763-682-5225 Fax: 763-684-6111 | |
Bridging Hope Counseling Services Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 311 Brighton Ave S, Suite B, Buffalo, MN 55313 Phone: 763-291-5505 Fax: 763-657-0819 |